SERZONE
LOE ApproachingNDAORALTABLET
Approved
Dec 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SERZONE is an oral small-molecule antidepressant approved by the FDA in 1994 for the treatment of depression. The drug's mechanism of action involves serotonin reuptake inhibition with additional noradrenergic activity. It represents a mature therapeutic option within the SSRI/SNRI class.
LOE Approaching
As a mature antidepressant approaching loss of exclusivity, the brand team is likely focused on retention and cost management rather than expansion, with smaller commercial infrastructure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on SERZONE represents a mature-stage, maintenance-focused career opportunity rather than a growth platform. The product offers stability in a well-understood therapeutic area but limited upside potential or skill-building opportunities in emerging modalities.
Brand ManagerField Sales Representative
Worked on SERZONE at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.